Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Innate Pharma S.A is a biotechnology business based in the US. Innate Pharma S-A shares (IPHA) are listed on the NASDAQ and all prices are listed in US Dollars. Innate Pharma S-A employs 212 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $3.81 |
|---|---|
| 52-week range | $3.02 - $11.95 |
| 50-day moving average | $4.94 |
| 200-day moving average | $4.54 |
| Wall St. target price | $9.64 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.12 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.81 from 2022-01-25
| 1 week (2022-01-19) | -11.40% |
|---|---|
| 1 month (2021-12-23) | -26.31% |
| 3 months (2021-10-26) | -32.69% |
| 6 months (2021-07-26) | 23.70% |
| 1 year (2021-01-26) | -9.50% |
|---|---|
| 2 years (2020-01-24) | -47.66% |
| 3 years (2019-01-22) | N/A |
| 5 years (2017-01-22) | N/A |
Valuing Innate Pharma S-A stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Innate Pharma S-A's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Innate Pharma S-A's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $38.3 million.
The EBITDA is a measure of a Innate Pharma S-A's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $49.4 million |
|---|---|
| Gross profit TTM | $11.8 million |
| Return on assets TTM | -7.43% |
| Return on equity TTM | -45.33% |
| Profit margin | -156.64% |
| Book value | $1.69 |
| Market capitalisation | $364.9 million |
TTM: trailing 12 months
We're not expecting Innate Pharma S-A to pay a dividend over the next 12 months.
Over the last 12 months, Innate Pharma S-A's shares have ranged in value from as little as $3.02 up to $11.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Innate Pharma S-A's is -0.0395. This would suggest that Innate Pharma S-A's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Innate Pharma S-A has bucked the trend.
Innate Pharma S. A. , a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway. Its products in preclinical trials include IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH61, NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers; IPH43, an anti-MICA/B antibody drug conjugate; Lumoxiti (moxetumomab pasudotox-tdfk), a tumor antigen targeting solution for the treatment of hairy cell leukemia; Anti-Siglec-9, an antibody program; IPH25, a checkpoint inhibitor; and IPH62, an NKp46-NKCE platform. Innate Pharma S. A.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.